These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7621247

  • 1. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
    Brysch W, Magal E, Louis JC, Kunst M, Klinger I, Schlingensiepen R, Schlingensiepen KH.
    Cancer Gene Ther; 1994 Jun; 1(2):99-105. PubMed ID: 7621247
    [Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
    Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP.
    Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
    [Abstract] [Full Text] [Related]

  • 3. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG, Ethier SP.
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [Abstract] [Full Text] [Related]

  • 4. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O, Hacker NF, Cho-Chung YS.
    Oncogene; 1999 Sep 02; 18(35):4999-5004. PubMed ID: 10490835
    [Abstract] [Full Text] [Related]

  • 5. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 6. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
    Shawver LK, Mann E, Elliger SS, Dugger TC, Arteaga CL.
    Cancer Res; 1994 Mar 01; 54(5):1367-73. PubMed ID: 7907001
    [Abstract] [Full Text] [Related]

  • 7. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.
    Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Ménard S.
    Oncogene; 1998 Jul 30; 17(4):425-32. PubMed ID: 9696035
    [Abstract] [Full Text] [Related]

  • 8. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides.
    Bertram J, Killian M, Brysch W, Schlingensiepen KH, Kneba M.
    Biochem Biophys Res Commun; 1994 Apr 15; 200(1):661-7. PubMed ID: 7909438
    [Abstract] [Full Text] [Related]

  • 9. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
    Tari AM, Hung MC, Li K, Lopez-Berestein G.
    Oncogene; 1999 Feb 11; 18(6):1325-32. PubMed ID: 10022814
    [Abstract] [Full Text] [Related]

  • 10. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG, Schelling ME, Hosick HL.
    Cell Growth Differ; 2000 Mar 11; 11(3):173-83. PubMed ID: 10768865
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
    Hwang MS, Yum YN, Joo JH, Kim S, Lee KK, Gee SW, Kang HI, Kim OH.
    Anticancer Res; 2001 Mar 11; 21(4A):2649-55. PubMed ID: 11724334
    [Abstract] [Full Text] [Related]

  • 12. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
    Roh H, Pippin J, Boswell C, Drebin JA.
    J Surg Res; 1998 Jun 11; 77(1):85-90. PubMed ID: 9698539
    [Abstract] [Full Text] [Related]

  • 13. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
    Ethier SP, Kokeny KE, Ridings JW, Dilts CA.
    Cancer Res; 1996 Feb 15; 56(4):899-907. PubMed ID: 8631031
    [Abstract] [Full Text] [Related]

  • 14. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
    Liu J, Spence MJ, Wallace PM, Forcier K, Hellström I, Vestal RE.
    Cell Growth Differ; 1997 Jun 15; 8(6):667-76. PubMed ID: 9186000
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 16. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells.
    Abdel-Mageed A, Agrawal KC.
    Cancer Gene Ther; 1997 Jun 01; 4(3):199-207. PubMed ID: 9171939
    [Abstract] [Full Text] [Related]

  • 17. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun 01; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

  • 18. HER2/neu antisense targeting of human breast carcinoma.
    Roh H, Pippin JA, Green DW, Boswell CB, Hirose CT, Mokadam N, Drebin JA.
    Oncogene; 2000 Dec 11; 19(53):6138-43. PubMed ID: 11156527
    [Abstract] [Full Text] [Related]

  • 19. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 11; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 20. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
    Kumar R, Mendelsohn J.
    Anticancer Res; 1994 Sep 11; 14(3A):1001-8. PubMed ID: 7915505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.